Drug Profile


Alternative Names: SH 636; ZK 117137

Latest Information Update: 19 Aug 2005

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Anti-inflammatories
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Multiple sclerosis

Most Recent Events

  • 01 Jan 2005 Discontinued - Preclinical for Inflammation in Germany (unspecified route)
  • 01 Jan 2005 Discontinued - Phase-II for Multiple sclerosis in USA (PO)
  • 16 Jul 2003 Preclinical trials in Inflammation in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top